Overview

A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients

Status:
Completed
Trial end date:
2019-11-19
Target enrollment:
Participant gender:
Summary
The objective of this study was to evaluate the safety profile of ELIGARD® in ethnic Asian prostate cancer patients.
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Singapore Pte. Ltd.
Treatments:
Leuprolide